Bioinvent International AB (PUBL) has implemented a rights issue
BioInvent International AB (publ), a research-based pharmaceutical company focused on developing antibody drugs, has carried out a rights issue with preferential right for the company’s shareholders. The rights issue, which was oversubscribed, will provide the company with approximately SEK 77,7 million.
BioInvent was advised by Mannheimer Swartling on the rights issue. The firm acted as project leader throughout the process and was responsible for the prospectus. Mannheimer Swartling’s team mainly consisted of Madeleine Rydberger, Jakob Wijkander and Klara Holm.